NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
As previously announced, Nabriva Therapeutics AG (the Company) will hold its Analyst and Investor Day on June 19, 2017. A copy of the presentation materials to be used by the Company at the Analyst and Investor Day is attached hereto as Exhibit 99.1 and is incorporated by reference into this Form 8-K.
The information in this Form 8-K, including Exhibits 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
See Exhibit Index attached hereto.
Nabriva Therapeutics AG ExhibitEX-99.1 2 a17-14242_3ex99d1.htm EX-99.1 Exhibit 99.1 A Transformational Year for Nabriva June 19,…To view the full exhibit click hereAbout NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH.